Reuters exclusively reported that U.S. life sciences company Illumina is in talks with European Union (EU) antitrust regulators to divest Grail ahead of an expected EU veto of its $7.1 billion acquisition of the biotechnology company. The European Commission confirmed the Reuters story the next day and blocked the deal because remedies offered by Illumina did not fully address the EU competition enforcer’s concerns.
Technology
05 September 2022, 7:16 pm. 1 minute
Article Tags
Topics of Interest: Technology
Type: Reuters Best
Sectors: Business & Finance
Regions: Europe
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Share this article
Sign up for email updates
Subscribe
Sign up for email updates